Drugs / Fotagliptin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05782192 | Jun 2019 → Mar 2022 | type 2 diabetes mellitus | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fotagliptin | “Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind,...” PMID 37814306 ↗ Oct 2023 |
| Action | Inhibit | “a novel DPP-4 inhibitor fotagliptin” PMID 37814306 ↗ Oct 2023 |